Protein-losing enteropathy


Cite item

Full Text

Abstract

Protein-losing enteropathy (PLE) is a rare complication of intestinal diseases. Its main manifestation is hypoproteinemic edema. The diagnosis of PLE is based on the verification of protein loss into the intestinal lumen, by determining fecal α1-antitrypsin concentration and clearance. The localization of the affected colonic segment is clarified using radiologic and endoscopic techniques. The mainstay of treatment for PLE is a fat-free diet enriched with medium-chain triglycerides. Surgical resection of the affected segment of the colon may be the treatment of choice for severe hypoproteinemia resistant to drug therapy.

About the authors

A I Parfenov

Московский клинический научно-практический центр ДЗМ

Москва, Россия

L M Krums

Московский клинический научно-практический центр ДЗМ

Москва, Россия

References

  1. Takeda H, Ishihama K, Fukui T. Significance of rapid turnover proteins in protein-losing gastroenteropathy. Hepatogastroenterol. 2003;50:1963-1965.
  2. Hokari R, Kitagawa N, Watanabe C, Komoto S, Kurihara C, Okada Y, Kawaguchi A, Nagao S, Hibi T, Miura S. Changes in regulatory molecules for lymphangiogenesis in intestinal lymphangiectasia with enteric protein loss. J Gastroenterol Hepatol 2008;23:e88-e95. doi: 10.1111/j.1440-1746.2007.05225.x
  3. Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol. 2010;105:43-49.
  4. Парфенов А.И., Екисенина Н.И., Мазо В.К., Гмошинский В.К., Сафонова С.А. Барьерная функция желудочно-кишечного тракта. Тер. архив 2000;2:64-66.
  5. Noimark L, Cox H. Nutritional problems related to food allergy in childhood. Pediat Allergy Immunol 2008;19:188-195.
  6. Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J Rare Dis 2008;3:5-10. doi: 10.1186/1750-1172-3-5
  7. Fuss IJ, Strober W, Cuccherini BA, Pearlstein GR, Bossuyt X, Brown M, Fleisher TA, Horgan K. Intestinal lymphangiectasia, a disease characterized by selective loss of naive CD45RA+ lymphocytes into the gastrointestinal tract. Eur J Immunol 1998;28:4275-4285. doi: 10.1002/(SICI)1521-4141(199812)28
  8. Парфенов А.И. Энтерология: Руководство для врачей. 2-е издание. М.: Медицинское информационное агентство; 2009.
  9. Парфенов А.И., Акопова А.О., Щербаков П.Л.,Михеева О.М., Хомерики С.Г. Видеокапсулная эндоскопия — еще один шаг на пути совершенствования диагностики болезней тонкой кишки. Тер. арх. 2016;4:5-11. doi: 10.17116/terarkh 20168844-8
  10. Takenaka H, Ohmiya N, Hirooka Y, Nakamura M, Ohno E, Miyahara R, Kawashima H, Itoh A, Watanabe O, Ando T, Goto H. Endoscopic and imaging findings in protein-losing enteropathy. J Clin Gastroenterol 2012;46:575-580. doi: 10.1097/MCG.0b013e31823832ac
  11. Lee HL, Han DS, Kim JB, Jeon YC, Sohn JH, Hahm JS. Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report. J Korean Med Sci 2004;19:466-469. doi: 10.3346/jkms.2004.19.3.466
  12. Desai A, Guvenc B, Carachi R. Evidence for medium chain triglycerides in the treatment of primairy intestinal lymphangiectasia. Eur J Ped Surg 2009;19:241-245.
  13. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander. Inflamm Bowel Dis. 2010;16:1620-1627.
  14. Ferrante M, Penninckx F, De Hertogh G, Geboes K, D’Hoore A, Noman M. Protein-losing enteropathy in Crohn’s disease. Acta Gastroenterol Belg. 2006;69:384-389.
  15. Cakir M, Ersoz S, Akbulut UE. Disseminated Cytomegalovirus Infection and Protein Losing Enteropathy as Presenting Feature of Pediatric Patient with Crohn’s Disease. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):60-65.
  16. Sano S, Yamagami K, Tanaka AA unique case of collagenous colitis presenting as proteinlosing enteropathy successfully treated with prednisolone. World J Gastroenterol. 2008;14(39):6083-6086. doi: 10.17116/terarkh20178924-9

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies